arrow
K

Kehang Li

The Chinese University of Hong Kong
H指数:10
被引数:375

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study

尼马曲韦/利托那韦和莫那比拉韦在降低新型冠状病毒肺炎短期和长期心血管并发症风险方面的有效性: 一项目标试验仿真研究

2025-12-210
OAAI
Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study

Nirmatrelvir-ritonavir立即开始治疗对COVID后结果的更大益处: 一项基于人群的回顾性队列研究

2025-11-100
OAAI
SARS-CoV-2 rebound and post-acute mortality and hospitalization among patients admitted with COVID-19: cohort study

新型冠状病毒肺炎患者的SARS-CoV-2反弹和急性后死亡率和住院: 队列研究

2025-07-280
OAAI
Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study

哮喘患者中尼玛特雷韦/利托那韦与莫诺拉韦的短期和长期比较疗效:一项队列研究

2025-02-280
OA
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation

nirmatrelvir/ritonavir和molnupiravir对门诊患者的post-COVID-19结果的有效性: 目标试验仿真研究

2025-02-180
OAAI
COVID-19 vaccination modified the effect of nirmatrelvir-ritonavir on post-acute mortality and rehospitalization: a retrospective cohort study

新型冠状病毒肺炎疫苗接种改善尼马瑞韦-利托那韦对急性后死亡率和再住院的影响: 一项回顾性队列研究

2024-11-040
OAAI
Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study

尼马曲韦-利托那韦与新型冠状病毒肺炎住院患者急性后遗症和死亡率的关系: 一项回顾性队列研究

2024-10-014
OAAI
Association between asthma and COVID-19 severity during Omicron epidemic: a retrospective cohort study using real-world data

Omicron流行期间哮喘与新型冠状病毒肺炎严重程度之间的关系: 一项使用真实数据的回顾性队列研究

2024-07-042
OAAI